Clinical trials: Thromboembolic Disease
Atrial Fibrillation
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm).
- Trial name
- X-VERT (NCT01674647)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- 178 sites in United States, Belgium and 15 more
- Volunteers
- 1,504 people
- Sponsor
- Bayer
Venous Thromboembolism, Urologic Cancer
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
Patients with genitourinary cancers (ex: bladder, testicular, kidney) are at high risk of developing blood clots if they receive systemic therapy (ex: chemotherapy, immunotherapy).
- Trial name
- PREVENT-GU (NCT05920343)
- Testing
- Rivaroxaban 10 MG
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Ottawa Hospital Research Institute
Vagina Atrophy
Vaginal Estrogen Treatment and Effect on Hemostatic Parameters in Postmenopausal Women
This study investigates whether vaginal estrogen treatment has an effect on hemostatic parameters in postmenopausal women. Blood samples are collected before and after 3 months treatment to assess changes in hemostasis.
- Trial name
- NCT07160504
- Testing
- Vaginal estradiol tablets
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- University of Aarhus
Post Thrombotic Syndrome, Deep Vein Thrombosis
Long-term Outcome After Heparin and Edoxaban Versus Heparin Plus Vit K Antagonists for Acute DVT and PE
Centers that participated in the HOKUSAI VTE trial will be invited to collect follow of previously enrolled patients at least 2 years after the index VTE.
- Conditions
- Post Thrombotic Syndrome, Deep Vein Thrombosis, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT03757481
- Testing
- no intervention
- Where
- 11 sites in France
- Volunteers
- 156 people
- Sponsor
- University Hospital, Montpellier
Cancer, Venous Thromboembolism
Management of Recurrent Venous Thromboembolism During Anticoagulant Treatment in Cancer Patients - a Prospective Cohort Study
Objective: To prospectively evaluate clinical outcomes during guideline-recommended LMWH dose escalation for recurrent VTE during LMWH or DOAC treatment for cancer-associated thrombosis.
- Conditions
- Cancer, Venous Thromboembolism, Recurrence
- Trial name
- REDUCE (NCT05229471)
- Where
- 9 sites in Italy, Netherlands and 1 more
- Volunteers
- 220 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Obesity
Venous Thromboprophylaxis in Bariatric Surgery
The main aim of this study is to compare the influence of total body-weight (TBW), lean body-weight (LBW), ideal body-weight (IBW) or Body Mass Index (BMI) on peak anti-Xa levels at steady-state in bariatric surgery (BS) morbidly…
- Trial name
- OBSUD (NCT03218514)
- Testing
- Dalteparin
- Volunteers
- 118 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Venous Thromboembolism
Weight Based Enoxaparin in Trauma Patients
Hospitalized trauma patients frequently suffer from blood clots in the legs or lungs. To minimize the risk of these blood clots developing, patients may be given a blood-thinner drug such as enoxaparin.
- Trial name
- WeBET (NCT01916707)
- Testing
- Dosing of enoxaparin for VTE prophylaxis
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- Intermountain Health Care, Inc.
Antiphospholipid Antibody Syndrome
Rivaroxaban for Antiphospholipid Antibody Syndrome
The antiphospholipid antibody syndrome (APS) is a syndrome associated with excessive blood clotting (thrombosis). APS is among the most common cause of heart attack and stroke in patients under the age of 50 and is particularly…
- Trial name
- RAPS (NCT02116036)
- Testing
- Rivaroxaban
- Where
- 6 sites in Canada
- Volunteers
- 81 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Chronic Thromboembolic Pulmonary Hypertension
Computerized Decision Support to Increase Detection of Chronic Thromboembolic Pulmonary Hypertension in Patients With Prior Pulmonary Embolism
To address the knowledge gap that exists among providers resulting in underdiagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), the investigators have devised this 400-patient single-center Quality Improvement…
- Trial name
- CTEPH-DETECT (NCT03729544)
- Testing
- On-screen computerized decision support alert
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
Arterial Thromboembolism, Venous Thromboembolism
Long-term Active Surveillance Study for Oral Contraceptives (LASS)
The objective of this study is to characterize and compare the risks of long-term use of oral contraceptives containing drospirenone and of other established oral contraceptives.
- Conditions
- Arterial Thromboembolism, Venous Thromboembolism, Breast Cancer
- Trial name
- NCT00676065
- Where
- Germany
- Volunteers
- 58,303 people, healthy volunteers welcome
- Sponsor
- Center for Epidemiology and Health Research, Germany
Lymphoma, Leukemia
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease
- Trial name
- HEM-DOAC (NCT07270263)
- Testing
- Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk
Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Acute Pulmonary Embolism (PE)
CTEPH Differential Diagnosis Assisted by Enhanced Large Language Model Support
This randomized controlled trial aims to evaluate whether a locked large language model (LLM)-based clinical decision support system improves the differential diagnosis of pulmonary artery filling defects among physicians who do…
- Conditions
- Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Acute Pulmonary Embolism (PE), Pulmonary Artery Sarcoma
- Trial name
- NCT07902011
- Testing
- Locked CTEPH-LLM Diagnostic Decision Support
- Where
- China
- Volunteers
- 60 people
- Sponsor
- China-Japan Friendship Hospital
Venous Thromboembolism, Fetal Death
Fetal Loss in Women With Unprovoked Thromboembolism (FLUTE)
The purpose of this study is to determine the risk of fetal loss in women with unprovoked venous thromboembolism (VTE) who do not have identifiable inherited thrombophilia compared with women who have the diagnosis of venous…
- Trial name
- NCT00149357
- Testing
- Thrombophilia Testing
- Where
- 5 sites in Australia, Canada
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- McMaster University
Venous Thromboembolism, Deep Vein Thrombosis
OsciPulse Device for the Prevention of VTE
This is a Phase 2 safety and tolerability trial that will take place in two parts. Part one of the trial will determine the tolerability of the OsciPulse device on healthy subjects who wear the device for up to three hours.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Thromboembolisms
- Trial name
- NCT04625673
- Testing
- OsciPulse
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Venous Thromboembolism, Digital Health
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management
Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management.
- Conditions
- Venous Thromboembolism, Digital Health, Health Education
- Trial name
- SmaVTE-RCT (NCT06350331)
- Testing
- mobile venous thromboembolism application (mVTEA)
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Navy General Hospital, Beijing
Deep Vein Thrombosis
Limited Compression Ultrasound by Emergency Physicians to Exclude Deep Vein Thrombosis
Deep vein thrombosis is a common condition seen in the Emergency Department. Standard of care for diagnosis of DVT includes a combination of a clinical pre-test probability rule known as Well's criteria, D-dimer blood testing…
- Trial name
- NCT01007045
- Where
- 2 sites in Canada
- Volunteers
- 227 people
- Sponsor
- Queen's University
Thrombosis
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
- Trial name
- NCT02981472
- Testing
- Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
- Where
- 46 sites in United States, Argentina and 12 more
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism
Impact of Early Debriefing and Enhanced Educative Components on Direct Oral Anticoagulant Adherence After Venous Thromboembolism.
Venous thromboembolism (VTE) is a frequent multifactorial and potential life-threatening disease. Once VTE has been diagnosed, anticoagulation should be started and prolonged for at least three to six months in order to reduce…
- Trial name
- DEBRIEF-VTE (NCT04141254)
- Testing
- Debriefing and educative components, Without debriefing and educative components
- Where
- 10 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Brest
Multiple Myeloma
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have…
- Trial name
- NCT02922543
- Where
- Japan
- Volunteers
- 361 people
- Sponsor
- Celgene
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years
Researchers are looking for a better way to treat people who have acute venous and arterial thrombotic and thromboembolic events. These are severe medical problems due to blood clots forming in and blocking blood vessels.
- Trial name
- NCT06562985
- Testing
- BAY3018250 Dose 1, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.